



Patent Attorney's Docket No. <u>001560-390</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re P	atent Application of)		
Haruka	azu FUKAMI et al) Group Art Unit: 1624		
Applic	ation No.: 09/763,213) Prior Examiner: Kahsay Habte		
Filed: For:	February 20, 2001 DESCRIPTION QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF AMENDMENT/REPLY TO	Confirmation No.: 3646 RECEIVED OCT 3 0 2002 TECH CENTER 1600/2900 RANSMITTAL LETTER		
		4-30-30-30-30-30-30-30-30-30-30-30-30-30-		
	ant Commissioner for Patents agton, D.C. 20231			
Sir:				
E	nclosed is a reply for the above-identified pa	itent application.		
[3	A Petition for Extension of Time is also	enclosed.		
[A Terminal Disclaimer and a check for requisite Government fee are also enclosed	[] \$55.00 (2814) [] \$110.00 (1814) to cover the sed.		
[] Also enclosed is	·		
]] Small entity status is hereby claimed.			
[Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the [] \$370.00 (2801) [] \$740.00 (1801) fee due under 37 C.F.R. § 1.17(e).			
	[] Applicant(s) previously submitted requested.	, on, for which continued examination is		
[Applicant(s) request suspension of action by the Office until at least _, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.			
[A Request for Entry and Consideration (146/246) is also enclosed.	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.		
[3	No additional claim fee is required.			

[] An additional claim fee is required, and is calculated as shown below:

		AMENDED	CLAIM	S	
	No. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims		MINUS =		× \$18.00 (1202) =	
Independent Claims		MINUS =		× \$84.00 (1201) =	-
If Amendment adds mu	ltiple depend	dent claims, add \$28	30.00 (1203)		
Total Amendment Fee					
If small entity status is	claimed, sub	otract 50% of Total	Amendment I	Fee	
TOTAL ADDITIONA	L FEE DUE	FOR THIS AME	NDMENT		

L	J	A claim fee in the	amount of \$ i	s enclosed.
[]	Charge \$	to Deposit Account No	. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Registration No. 36,607

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: October 25, 2002

Java #39,300



#10C

Patent Attorney's Docket No. <u>001560-390</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Patent Application of	OC1 3 0 2002
Harukazu FUKAMI et al) Group Art Unit: 1624 TECH CENTER 1600/290
Application No.: 09/763,213) Prior Examiner: Kahsay Habte
Filed: February 20, 2001) Confirmation No.: 3646
For: DESCRIPTION QUINAZO DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREO))

REPLY AND AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In complete response to the Office Action mailed April 25, 2002, please amend the above-identified application as follows.

IN THE ABSTRACT:

Please replace the Abstract with the new Abstract attached hereto.

IN THE SPECIFICATION:

Kindly replace the paragraph beginning at page 4, line 10, with the following:

--R¹ represents a hydroxyl group, an amino group, a C_1 to C_4 lower alkylamino group which may be substituted with a carboxylic acid group, a C_7 and C_{10} lower aralkylamino group which may be substituted with a carboxylic acid group, an amino group acylated with a C_1 to C_4 lower aliphatic acid which may be substituted with a carboxylic